Login to Your Account

Precision approach to head and neck cancer turns Kura Oncology shares red hot

By Michael Fitzhugh
Staff Writer

Friday, September 8, 2017

Kura Oncology Inc. shares shot 72.3 percent higher Friday on news that its lead candidate, tipifarnib, hit the primary endpoint of a phase II trial in HRAS-mutant relapsed or refractory squamous cell carcinomas of the head and neck before the trial had even completed enrolling.

To continue reading subscribe now to Latest News

Learn More about Latest News

Already a subscriber? Sign In or Buy now to activate your subscription